ABUS
Arbutus Biopharma Corporation
Price Chart
Latest Quote
$4.39
Current Price| Previous Close | $4.13 |
| Open | $4.13 |
| Day High | $4.60 |
| Day Low | $3.50 |
| Volume | 5,293,532 |
Stock Information
| Shares Outstanding | 192.32M |
| Total Debt | $4.61M |
| Cash Equivalents | $93.70M |
| Revenue | $14.61M |
| Net Income | $-42.28M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $844.30M |
| EPS (TTM) | $-0.23 |
| Exchange | NMS |
đ Custom Metrics & Score
Score: 14/42| Debt to Equity | 0.01 |
| Debt to Earnings | -0.02 |
| Current Ratio | 8.15 |
| Quick Ratio | 8.01 |
| Avg Revenue Growth | -10.96% |
| Profit Margin | -1133.04% |
| Return on Equity | -71.81% |
| Avg FCF Growth | -1.21% |
| FCF Yield | -7.70% |
Score Explanation: The perfect score is 42/42 based on debt levels, profitability, growth rates, and cash flow metrics. FCF Yield is weighted most heavily as it shows what return the business currently generates.
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-02-02 | $4.39 | 5,293,532 |
| 2026-01-30 | $4.13 | 886,000 |
| 2026-01-29 | $4.13 | 674,400 |
| 2026-01-28 | $4.14 | 1,197,100 |
| 2026-01-27 | $4.16 | 648,300 |
| 2026-01-26 | $4.08 | 700,600 |
| 2026-01-23 | $4.06 | 1,143,000 |
| 2026-01-22 | $4.16 | 835,300 |
| 2026-01-21 | $4.14 | 1,290,400 |
| 2026-01-20 | $4.21 | 2,574,400 |
| 2026-01-16 | $4.06 | 8,517,400 |
| 2026-01-15 | $4.70 | 665,900 |
| 2026-01-14 | $4.78 | 710,900 |
| 2026-01-13 | $4.74 | 1,032,600 |
| 2026-01-12 | $4.50 | 1,010,000 |
| 2026-01-09 | $4.62 | 902,000 |
| 2026-01-08 | $4.65 | 1,369,500 |
| 2026-01-07 | $4.88 | 1,572,400 |
| 2026-01-06 | $4.79 | 1,169,100 |
| 2026-01-05 | $4.71 | 800,100 |
About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 1 and phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
đ° Latest News
Sector Update: Health Care Stocks Retreat Late Afternoon
MT Newswires âĸ 2026-01-16T20:57:25ZSector Update: Health Care Stocks Softer Friday Afternoon
MT Newswires âĸ 2026-01-16T18:47:28ZArbutus (ABUS) Upgraded to Buy: Here's What You Should Know
Zacks âĸ 2026-01-12T17:00:04Z
Are Medical Stocks Lagging Arbutus Biopharma (ABUS) This Year?
Zacks âĸ 2025-10-03T13:40:03Z
Is Arbutus Biopharma (ABUS) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-09-01T13:40:02Z
Is Aquestive Therapeutics (AQST) Stock Outpacing Its Medical Peers This Year?
Zacks âĸ 2025-08-14T13:40:02Z
Arbutus Biopharma (ABUS) Beats Q2 Earnings and Revenue Estimates
Zacks âĸ 2025-08-06T12:40:01Z
Arbutus: Q2 Earnings Snapshot
Associated Press Finance âĸ 2025-08-06T11:45:17ZArbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates
Zacks âĸ 2025-05-14T12:45:02Z
Arbutus: Q1 Earnings Snapshot
Associated Press Finance âĸ 2025-05-14T11:39:05ZIncome Statement (Annual)
Revenue
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Revenue | $6,171,000 | $18,141,000 | $39,019,000 | $10,988,000 |
| Operating Revenue | $6,171,000 | $18,141,000 | $39,019,000 | $10,988,000 |
Expenses
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Interest Expense | $137,000 | $459,000 | $1,726,000 | $2,857,000 |
| Total Expenses | $76,145,000 | $96,175,000 | $102,242,000 | $82,638,000 |
| Other Income Expense | $-6,394,000 | $-44,000 | $-2,255,000 | $-1,867,000 |
| Net Non Operating Interest Income Expense | $6,448,000 | $5,229,000 | $466,000 | $-2,730,000 |
| Interest Expense Non Operating | $137,000 | $459,000 | $1,726,000 | $2,857,000 |
| Operating Expense | $76,145,000 | $96,175,000 | $102,242,000 | $82,638,000 |
| General And Administrative Expense | $22,108,000 | $22,475,000 | $17,834,000 | $17,136,000 |
Income & Earnings
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Income From Continuing Operation Net Minority Interest | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Net Interest Income | $6,448,000 | $5,229,000 | $466,000 | $-2,730,000 |
| Interest Income | $6,585,000 | $5,688,000 | $2,192,000 | $127,000 |
| Normalized Income | $-63,526,000 | $-72,805,000 | $-67,674,550 | $-74,380,000 |
| Net Income From Continuing And Discontinued Operation | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Total Operating Income As Reported | $-76,319,000 | $-78,103,000 | $-65,456,000 | $-73,522,000 |
| Net Income Common Stockholders | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-88,386,000 |
| Net Income | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Net Income Including Noncontrolling Interests | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Net Income Continuous Operations | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Pretax Income | $-69,920,000 | $-72,849,000 | $-65,012,000 | $-76,247,000 |
| Special Income Charges | $-6,345,000 | $-69,000 | $-2,233,000 | $-1,872,000 |
| Interest Income Non Operating | $6,585,000 | $5,688,000 | $2,192,000 | $127,000 |
| Operating Income | $-69,974,000 | $-78,034,000 | $-63,223,000 | $-71,650,000 |
| Earnings From Equity Interest | - | - | - | $0 |
Per Share Metrics
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Diluted EPS | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
| Basic EPS | $-0.38 | $-0.44 | $-0.46 | $-0.83 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Tax Effect Of Unusual Items | $0 | $0 | $-473,550 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-62,009,000 | $-70,942,000 | $-59,604,000 | $-69,770,000 |
| Total Unusual Items | $-6,394,000 | $-44,000 | $-2,255,000 | $-1,867,000 |
| Total Unusual Items Excluding Goodwill | $-6,394,000 | $-44,000 | $-2,255,000 | $-1,867,000 |
| Reconciled Depreciation | $1,380,000 | $1,404,000 | $1,427,000 | $1,753,000 |
| EBITDA (Bullshit earnings) | $-68,403,000 | $-70,986,000 | $-61,859,000 | $-71,637,000 |
| EBIT | $-69,783,000 | $-72,390,000 | $-63,286,000 | $-73,390,000 |
| Diluted Average Shares | $185,608,874 | $165,960,379 | $150,939,337 | $106,242,452 |
| Basic Average Shares | $185,608,874 | $165,960,379 | $150,939,337 | $106,242,452 |
| Diluted NI Availto Com Stockholders | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-88,386,000 |
| Tax Provision | $0 | $0 | $4,444,000 | $0 |
| Restructuring And Mergern Acquisition | $6,345,000 | $69,000 | $2,233,000 | $1,872,000 |
| Gain On Sale Of Security | $-49,000 | $25,000 | $-22,000 | $5,000 |
| Research And Development | $54,037,000 | $73,700,000 | $84,408,000 | $65,502,000 |
| Selling General And Administration | $22,108,000 | $22,475,000 | $17,834,000 | $17,136,000 |
| Other Gand A | $22,108,000 | $22,475,000 | $17,834,000 | $17,136,000 |
| Otherunder Preferred Stock Dividend | - | - | $0 | $12,139,000 |
Balance Sheet (Annual)
Assets
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Net Tangible Assets | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Total Assets | $131,707,000 | $144,401,000 | $195,419,000 | $204,485,000 |
| Total Non Current Assets | $4,391,000 | $12,374,000 | $44,280,000 | $43,824,000 |
| Other Non Current Assets | $34,000 | - | $103,000 | $61,000 |
| Investmentin Financial Assets | $0 | $6,284,000 | $37,363,000 | $35,688,000 |
| Current Assets | $127,316,000 | $132,027,000 | $151,139,000 | $160,661,000 |
| Other Current Assets | $2,284,000 | $4,248,000 | $2,874,000 | $4,445,000 |
| Receivables | $2,409,000 | $1,776,000 | $1,352,000 | $899,000 |
| Accounts Receivable | $2,409,000 | $1,776,000 | $1,352,000 | $899,000 |
| Cash Cash Equivalents And Short Term Investments | $122,623,000 | $126,003,000 | $146,913,000 | $155,317,000 |
| Cash And Cash Equivalents | $36,330,000 | $26,285,000 | $30,776,000 | $109,282,000 |
| Prepaid Assets | - | - | - | $4,445,000 |
Debt
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Debt | $1,289,000 | $1,768,000 | $2,187,000 | $2,614,000 |
| Long Term Debt And Capital Lease Obligation | $806,000 | $1,343,000 | $1,815,000 | $2,231,000 |
| Current Debt And Capital Lease Obligation | $483,000 | $425,000 | $372,000 | $383,000 |
Liabilities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Total Liabilities Net Minority Interest | $34,341,000 | $38,383,000 | $58,567,000 | $35,046,000 |
| Total Non Current Liabilities Net Minority Interest | $18,723,000 | $15,896,000 | $25,710,000 | $23,825,000 |
| Other Non Current Liabilities | $15,054,000 | $14,553,000 | $17,896,000 | $21,594,000 |
| Non Current Deferred Liabilities | $2,863,000 | $0 | $5,999,000 | $0 |
| Current Liabilities | $15,618,000 | $22,487,000 | $32,857,000 | $11,221,000 |
| Current Deferred Liabilities | $7,571,000 | $11,791,000 | $16,456,000 | $0 |
| Payables And Accrued Expenses | $7,564,000 | $10,271,000 | $16,029,000 | $10,838,000 |
| Payables | $2,316,000 | $3,223,000 | $3,520,000 | $3,174,000 |
| Accounts Payable | $2,316,000 | $3,223,000 | $3,520,000 | $3,174,000 |
| Other Current Liabilities | - | - | - | $26,000 |
Equity
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Common Stock Equity | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Total Equity Gross Minority Interest | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Stockholders Equity | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Gains Losses Not Affecting Retained Earnings | $-48,135,000 | $-48,421,000 | $-50,488,000 | $-48,335,000 |
| Other Equity Adjustments | $-48,135,000 | $-48,421,000 | $-50,488,000 | $-48,335,000 |
| Retained Earnings | $-1,346,572,000 | $-1,276,652,000 | $-1,203,803,000 | $-1,134,347,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Ordinary Shares Number | $189,963,492 | $169,867,414 | $157,455,363 | $144,987,736 |
| Share Issued | $189,963,492 | $169,867,414 | $157,455,363 | $144,987,736 |
| Tangible Book Value | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Invested Capital | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Working Capital | $111,698,000 | $109,540,000 | $118,282,000 | $149,440,000 |
| Capital Lease Obligations | $1,289,000 | $1,768,000 | $2,187,000 | $2,614,000 |
| Total Capitalization | $97,366,000 | $106,018,000 | $136,852,000 | $169,439,000 |
| Additional Paid In Capital | $82,048,000 | $81,270,000 | $72,406,000 | $65,485,000 |
| Capital Stock | $1,410,025,000 | $1,349,821,000 | $1,318,737,000 | $1,286,636,000 |
| Common Stock | $1,410,025,000 | $1,349,821,000 | $1,318,737,000 | $1,286,636,000 |
| Non Current Deferred Revenue | $2,863,000 | $0 | $5,999,000 | $0 |
| Long Term Capital Lease Obligation | $806,000 | $1,343,000 | $1,815,000 | $2,231,000 |
| Current Deferred Revenue | $7,571,000 | $11,791,000 | $16,456,000 | $0 |
| Current Capital Lease Obligation | $483,000 | $425,000 | $372,000 | $383,000 |
| Current Accrued Expenses | $5,248,000 | $7,048,000 | $12,509,000 | $7,664,000 |
| Investments And Advances | $0 | $6,284,000 | $37,363,000 | $35,688,000 |
| Held To Maturity Securities | $0 | $6,284,000 | $37,363,000 | - |
| Net PPE | $4,357,000 | $6,090,000 | $6,814,000 | $8,075,000 |
| Accumulated Depreciation | $-12,996,000 | $-11,900,000 | $-10,801,000 | $-9,374,000 |
| Gross PPE | $17,353,000 | $17,990,000 | $17,615,000 | $17,449,000 |
| Leases | $8,590,000 | $8,590,000 | $8,590,000 | $8,563,000 |
| Other Properties | $8,286,000 | $9,009,000 | $8,634,000 | $8,500,000 |
| Machinery Furniture Equipment | $477,000 | $391,000 | $391,000 | $386,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $86,293,000 | $99,718,000 | $116,137,000 | $46,035,000 |
| Available For Sale Securities | - | - | $37,363,000 | $35,688,000 |
| Preferred Stock | - | - | - | $0 |
Cash Flow Statement (Annual)
Free Cash Flow
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Free Cash Flow | $-65,032,000 | $-86,944,000 | $-35,868,000 | $-68,341,000 |
Operating Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Operating Cash Flow | $-64,850,000 | $-85,936,000 | $-35,356,000 | $-67,532,000 |
| Cash Flow From Continuing Operating Activities | $-64,850,000 | $-85,936,000 | $-35,356,000 | $-67,532,000 |
| Operating Gains Losses | - | $-20,000 | - | $-5,000 |
Investing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Capital Expenditure | $-182,000 | $-1,008,000 | $-512,000 | $-809,000 |
| Investing Cash Flow | $22,948,000 | $50,773,000 | $-74,942,000 | $-12,678,000 |
| Cash Flow From Continuing Investing Activities | $22,948,000 | $50,773,000 | $-74,942,000 | $-12,678,000 |
Financing Activities
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| Issuance Of Capital Stock | $44,123,000 | $29,852,000 | $20,324,000 | $134,665,000 |
| Financing Cash Flow | $51,996,000 | $30,647,000 | $31,814,000 | $137,236,000 |
| Cash Flow From Continuing Financing Activities | $51,996,000 | $30,647,000 | $31,814,000 | $137,236,000 |
| Net Common Stock Issuance | $44,123,000 | $29,852,000 | $20,324,000 | $134,665,000 |
| Common Stock Issuance | $44,123,000 | $29,852,000 | $20,324,000 | $134,665,000 |
Other
| Metric | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| End Cash Position | $36,330,000 | $26,285,000 | $30,776,000 | $109,282,000 |
| Beginning Cash Position | $26,285,000 | $30,776,000 | $109,282,000 | $52,251,000 |
| Effect Of Exchange Rate Changes | $-49,000 | $25,000 | $-22,000 | $5,000 |
| Changes In Cash | $10,094,000 | $-4,516,000 | $-78,484,000 | $57,026,000 |
| Proceeds From Stock Option Exercised | $7,873,000 | $795,000 | $11,490,000 | $2,571,000 |
| Net Investment Purchase And Sale | $23,130,000 | $51,761,000 | $-74,430,000 | $-11,869,000 |
| Sale Of Investment | $164,639,000 | $132,270,000 | $56,000,000 | $70,350,000 |
| Purchase Of Investment | $-141,509,000 | $-80,509,000 | $-130,430,000 | $-82,219,000 |
| Net PPE Purchase And Sale | $-182,000 | $-988,000 | $-512,000 | $-809,000 |
| Sale Of PPE | $0 | $20,000 | $0 | - |
| Purchase Of PPE | $-182,000 | $-1,008,000 | $-512,000 | $-809,000 |
| Change In Working Capital | $-2,829,000 | $-18,233,000 | $29,243,000 | $925,000 |
| Change In Other Working Capital | $-1,357,000 | $-10,664,000 | $22,455,000 | - |
| Change In Other Current Liabilities | $-430,000 | $-444,000 | $-405,000 | $-374,000 |
| Change In Payables And Accrued Expense | $-2,707,000 | $-5,758,000 | $5,216,000 | $1,911,000 |
| Change In Prepaid Assets | $2,298,000 | $-943,000 | $2,430,000 | $-1,025,000 |
| Change In Receivables | $-633,000 | $-424,000 | $-453,000 | $413,000 |
| Changes In Account Receivables | $-633,000 | $-424,000 | $-453,000 | $413,000 |
| Other Non Cash Items | $501,000 | $-3,343,000 | $-3,698,000 | $-1,386,000 |
| Stock Based Compensation | $8,986,000 | $9,301,000 | $7,182,000 | $6,424,000 |
| Asset Impairment Charge | $167,000 | $0 | - | - |
| Amortization Of Securities | $-3,135,000 | $-2,196,000 | $-54,000 | $999,000 |
| Depreciation Amortization Depletion | $1,380,000 | $1,404,000 | $1,427,000 | $1,753,000 |
| Depreciation And Amortization | $1,380,000 | $1,404,000 | $1,427,000 | $1,753,000 |
| Depreciation | $1,380,000 | $1,404,000 | $1,427,000 | $1,753,000 |
| Gain Loss On Sale Of PPE | $0 | $-20,000 | $0 | - |
| Net Income From Continuing Operations | $-69,920,000 | $-72,849,000 | $-69,456,000 | $-76,247,000 |
| Change In Payable | - | - | $5,216,000 | $1,911,000 |
| Change In Account Payable | - | - | $5,216,000 | $1,911,000 |
| Net Foreign Currency Exchange Gain Loss | - | - | - | $-5,000 |